U.S., Oct. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07896811) titled 'Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma' on Oct. 20.
Brief Summary: The investigators propose a phase II signal-finding study, TRIFECTA-SCC, to determine whether four 100 mg IV every 6 week doses of vilastobart plus six every 4 week doses of Opdualag with induction radiotherapy can lead to >=50% 6-month progression-free survival for patients with recurrent and/or metastatic squamous cell carcinoma. Patients with pathology-confirmed squamous cell carcinoma, previously untreated in the recurrent and/or metastatic setting, and adequate organ function will be included.
Study Start Date: Feb....